In 2019, the FDA's Center for Drug Evaluation and Research (CDER) approved 48 novel drugs \[<https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019>\],^[@CR1]^ which was fewer than the all-time record of 62 NTD approvals in 2018,^[@CR2]^ but it was still a fruitful year. Among these approved drugs, 39 were targeted drugs (Table [1](#Tab1){ref-type="table"}), including 27 small molecules, 3 antibody-drug conjugates (ADCs), 1 RNA interference (RNAi) therapy, 1 antisense oligonucleotide, 4 monoclonal antibodies (mAbs), 1 recombinant fusion protein, and 2 synthetic peptide analogs. The targets included kinases, ion channels, exons, enzymes, and receptors. Oncology, which remains the most important drug discovery area, accounted for 23% (9/39) of the targeted drug approvals.Table 1Targeted drugs approved by the FDA in 2019No.Brand nameActive ingredientApproval dateTarget/ActivityFDA-approved use on approval date\*Drug classCompany1EgatenTriclabendazole2/13/2019Microtubule/tubulinTo treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly affect the liver, sometimes referred to as "liver flukes"Small moleculeNovartis Inc.2ZulressoBrexanolone3/19/2019GABA receptorTo treat postpartum depression (PPD) in adult womenSmall moleculeSage Therapeutics3SunosiSolriamfetol3/20/2019Dopamine and norepinephrine transportersTo treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apneaSmall moleculeJazz Pharmaceuticals4MayzentSiponimod3/26/2019Sphingosine-1-phosphate (S1P) receptorTo treat adults with relapsing forms of multiple sclerosisSmall moleculeNovartis Inc.5EvenityRomosozumab-aqqg4/9/2019SclerostinTo treat osteoporosis in postmenopausal women at high risk of fractureMonoclonal antibody (mAb)Amgen6BalversaErdafitinib4/12/2019FGFR familyTo treat adult patients with locally advanced or metastatic bladder cancerSmall moleculeJanssen Biotech7SkyriziRisankizumab-rzaa4/23/2019Interleukin-23 (IL-23)To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapyMonoclonal antibody (mAb)AbbVie Inc.8VyndaqelTafamidis meglumine5/3/2019Selective transthyretin (TTR) stabilizerTo treat heart disease (cardiomyopathy) caused by transthyretin-mediated amyloidosis (ATTR-CM) in adultsSmall moleculeFOLDRX Pharms9PiqrayAlpelisib5/24/2019PI3Kα inhibitorTo treat breast cancerSmall moleculeNovartis Inc.10PolivyPolatuzumab vedotin-piiq6/10/2019Anti-CD79b antibody-drug conjugate (ADC)To treat adult patients with relapsed or refractory diffuse large B-cell lymphomaAntibody-drug conjugate (ADC)Genentech Inc.11VyleesiBremelanotide6/21/2019Melanocortin 4 receptor agonistTo treat hypoactive sexual desire disorder in premenopausal womenSynthetic peptide analogAMAG Pharmaceuticals12XpovioSelinexor7/3/2019Selective CRM1 inhibitorTo treat adult patients with relapsed or refractory multiple myeloma (RRMM)Small moleculeKaryopharm Therapeutics Inc.13RecarbrioImipenem, cilastatin and relebactam7/16/2019Imipenem: β-lactamase inhibitor (previously FDA-approved antibiotic) cilastatin: dehydropeptidase inhibitor (previously FDA-approved antibiotic) relebactam: new β-lactamase inhibitorTo treat complicated urinary tract and intra-abdominal infectionsSmall moleculeMerck & Co., Inc.14NubeqaDarolutamide7/30/2019Androgen receptor (AR) antagonistTo treat adult patients with nonmetastatic castration-resistant prostate cancerSmall moleculeBayer Healthcare15TuralioPexidartinib8/2/2019Colony-stimulating factor 1 receptor (CSF1R)To treat adult patients with symptomatic tenosynovial giant cell tumorSmall MoleculeDaiichi Sankyo Inc.16WakixPitolisant8/14/2019Histamine H3 receptor inverse agonistTo treat excessive daytime sleepiness (EDS) in adult patients with narcolepsySmall moleculeHarmony Biosciences17RozlytrekEntrectinib8/15/2019pan-Trk, ROS1, and ALK inhibitorTo treat adult patients with metastatic, ROS1-positive non-small-cell lung cancer (NSCLC)Small moleculeGenentech Inc.18InrebicFedratinib8/16/2019JAK2 inhibitorTo treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosisSmall moleculeImpact Biomedicines, Inc.19RinvoqUpadacitinib8/16/2019Janus kinase 1 (JAK1) inhibitorTo treat adults with moderately to severely active rheumatoid arthritisSmall moleculeAbbVie Inc.20XenletaLefamulin8/19/201950S bacterial ribosomeTo treat adults with community-acquired bacterial pneumoniaSmall moleculeNabriva Therapeutics21NourianzIstradefylline8/27/2019Adenosine A2A receptor antagonistTo treat adult patients with Parkinson's disease experiencing "off" episodesSmall moleculeKyowa Kirin, Inc.22IbsrelaTenapanor9/12/2019Na+/H+ exchanger NHE3 inhibitorTo treat irritable bowel syndrome with constipation in adultsSmall moleculeArdelyx, Inc.23AkliefTrifarotene10/4/2019Retinoic acid receptor (RAR) agonistFor the topical treatment of acne vulgaris in patients 9 years of age and olderSmall moleculeGalderma R&D24BeovuBrolucizumab-dbll10/7/2019Vascular endothelial growth factor (VEGF) inhibitorTo treat wet age-related macular degenerationMonoclonal antibody (mAb)Novartis Pharmaceuticals Corporation25ScenesseAfamelanotide10/8/2019Melanocortin 1 receptorTo increase pain-free light exposure in adult patients with a history of phototoxic reactions (skin damage) from erythropoietic protoporphyriaSynthetic peptide analogClivunel Inc.26ReyvowLasmiditan10/11/20195-HT1F receptor agonistFor the acute treatment of migraine with or without aura in adultsSmall moleculeEli Lilly27TrikaftaElexacaftor/ivacaftor/tezacaftor10/21/2019Elexacaftor: new cystic fibrosis transmembrane conductance regulator (CFTR) modulator ivacaftor: CFTR potentiator tezacaftor: F508del CFTR correctorTo treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosisSmall moleculeVertex Pharmaceuticals28ReblozylLuspatercept-aamt11/8/2019Binds several TGF-beta superfamily ligandsFor the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusionsRecombinant fusion proteinCelgene Corporation and Acceleron Pharma Inc.29BrukinsaZanubrutinib11/14/2019Bruton tyrosine kinase (BTK) inhibitorTo treat certain patients with mantle cell lymphoma, a form of blood cancerSmall moleculeBeiGene USA Inc.30AdakveoCrizanlizumab-tmca11/15/2019P-selectinTo treat patients with painful complications of sickle cell diseaseMonoclonal antibody (mAb)Novartis Inc.31GivlaariGivosiran11/20/2019Aminolevulinic acid synthase 1 (ALAS1)To treat acute hepatic porphyria, a rare blood disorderGene therapy: RNA interference (RNAi)Alnylam Pharmaceuticals32XcopriCenobamate11/21/2019Sodium channel blockerTo treat partial onset seizuresSmall moleculeSK Life Science, Inc.33OxbrytaVoxelotor11/25/2019Sickle hemoglobin (HbS) polymerization inhibitorTo treat sickle cell diseaseSmall moleculeOxbryta to Global Blood Therapeutics34Vyondys 53Golodirsen12/12/2019Exon 53To treat certain patients with Duchenne muscular dystrophyGene therapy: antisense oligonucleotideSarepta Therapeutics35PadcevEnfortumab vedotin-ejfv12/18/2019Nectin-4To treat refractory bladder cancerAntibody-drug conjugate (ADC)Seattle Genetics36CaplytaLumateperone tosylate12/20/20195-HT2A receptor antagonistTo treat schizophreniaSmall moleculeIntra-Cellular Therapies, Inc.37DayvigoLemborexant12/20/2019Dual antagonist of the orexin OX1 and OX2 receptorsTo treat insomniaSmall moleculeEisai Inc.38EnhertuFam-trastuzumab deruxtecan-nxki12/20/2019Trastuzumab: epidermal growth factor receptor 2 (HER2) deruxtecan: DNA topoisomerase I inhibitorTo treat metastatic breast cancerAntibody-drug conjugate (ADC)AstraZeneca and Daiichi Sankyo Company, Limited39UbrelvyUbrogepant12/23/2019Calcitonin gene-related peptide receptor (CGRP) antagonistFor the acute treatment of migraine with or without aura in adultsSmall moleculeAllergan USA, Inc.

Small molecule drugs play an important role in fighting diseases. Although the development of small molecules has slowed slightly in recent years, the 27 small molecule targeted drugs approved in 2019 accounted for nearly 70% of the total number of approved targeted drugs. Small molecule drugs have the advantages of oral bioavailability, pharmacokinetics, drug delivery, production cost, etc., which facilitate the development of this class of drugs, and this comparative advantage will continue in the near future. In addition, small molecules may be used in conjunction with new types of therapies, such as antibody-drug conjugates (ADCs).

In 2019, there was an increase in the number of approved ADCs: polatuzumab vedotin-piiq (Polivy) for relapsed or refractory diffuse large B-cell lymphoma, enfortumab vedotin-ejfv (Padcev) for refractory bladder cancer and fam-trastuzumab deruxtecan-nxki (Enhertu) for metastatic breast cancer. ADCs comprise a monoclonal antibody and cytotoxic agents conjugated via a chemical linker. The specificity of mAbs allows the chemotherapy agents to be selectively delivered to targeted cancer cells, thereby reducing toxicity. Importantly, mAbs such as trastuzumab not only show specificity but also have anticancer effects. To date, seven ADCs have been approved by the FDA for clinical use, and over 100 ADCs are in clinical development.^[@CR3]^

Two synthetic peptide analogs were approved this year, bremelanotide and afamelanotide. Peptide-based therapy has been applied in various diseases, such as infectious diseases, allergic diseases, autoimmune diseases, sexual dysfunction, and fibrosis. Many efforts have been made to discover novel bioactive peptides. There is much potential for peptide-based therapy.

Another surprising newly emerging field in 2019 was gene therapy. In 2019, two gene therapy products were approved---Givlaari (givosiran) from Alnylam Pharmaceuticals and Vyondys 53 (golodirsen) from Sarepta Therapeutics. Givlaari is an RNA interference (RNAi) therapeutic that targets aminolevulinic acid synthase 1 (ALAS1) to treat acute hepatic porphyria (AHP). This is the second RNAi therapy approved by the FDA; Onpattro (patisiran) was the first. Onpattro was also developed by Alnylam Pharmaceuticals and was approved by the FDA in 2018 to treat hereditary TTR-mediated amyloidosis. Both drugs use enhanced stabilization chemistry (ESC)-GalNAc conjugate technology. Vyondys 53 is an antisense oligonucleotide developed from Sarepta's phosphorodiamidate morpholino oligomer (PMO) platform; it was approved to treat Duchenne muscular dystrophy (DMD) patients who have a confirmed mutation of the dystrophin gene that causes exon 53 skipping. In the future, more gene therapies currently under development are likely to be approved in the upcoming years, which would bring hope to individuals with severe, life-threatening diseases or rare diseases.

The FDA approved Brukinsa (zanubrutinib) capsules from BeiGene USA, Inc., for the treatment of adult patients with mantle cell lymphoma who received at least one prior therapy. Brukinsa is the first novel anticancer drug developed by a Chinese company and approved by the FDA. It was granted Accelerated Approval, Breakthrough Therapy designation, and Orphan Drug designation. Unfortunately, BeiGene, Ltd., announced that the new drug application (NDA) for zanubrutinib for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) was accepted by the National Medical Products Administration (NMPA) on 08/27/2018, but zanubrutinib has not yet been approved.

On 08/30/2018, the China Food and Drug Administration (CFDA) changed its name to the National Medical Products Administration (NMPA), which is administered by the State Administration for Market Regulation (SAMR). In 2019, the NMPA approved 51 new drugs. Herein, we only summarize the eight innovative targeted drugs developed by the Chinese pharmaceutical industry (Table [2](#Tab2){ref-type="table"}), including five small molecules, one antibiotic, one synthetic peptide analog, and two mAbs.Table 2Targeted drugs developed by Chinese pharmaceutical companies that were approved by the NMPA in 2019No.Drug nameActive ingredientApproval dateTarget/ActivityCFDA-approved use on approval date\*Drug classCompany1BiteCarrimycin6/24/19β-lactamaseBacterial infection of the upper respiratory tract, resistant *Mycobacterium tuberculosis* infectionSmall moleculeShengyang Tonglian Group Co., Ltd.2Fu Laimei Polyethylene Glycol Loxenatide InjectionPEG-loxenatide5/7/19GLP-1 receptor antagonistType 2 diabetesSynthetic peptide analogHansoh Pharma3Camrelizumab5/30/19PD-1 inhibitorRecurrent or refractory classical Hodgkin lymphomaMonoclonal antibody (mAb)Jiangsu Hengrui Medicine Co., Ltd.4XinbikeBenvitimod5/31/19Aryl hydrocarbon receptor (AhR) agonistPsoriasisSmall moleculeTianji Pharma5GV-971Sodium oligomannate11/2/19gut microbiotaMild to moderate Alzheimer's diseaseSmall moleculeGreen Valley6Flumatinib mesylate11/26/19BCR-Abl inhibitorChronic myelogenous leukemiaSmall moleculeHansoh Pharma7ZEJULANiraparib tosylate12/27/19PARP1/2 inhibitorRecurrent epithelial ovarian cancerSmall moleculeZai Lab8Tislelizumab12/27/19PD-1 inhibitorClassical Hodgkin lymphoma (cHL)Monoclonal antibody (mAb)BeiGene9Remimazolam tosylate12/27/19GABA~A~ receptor antagonistSedation for routine gastroscopySmall moleculeJiangsu Hengrui Medicine Co. Ltd.

Two cancer immunotherapy drugs that target PD-1 have been approved, camrelizumab from Jiangsu Hengrui Medicine Co. and tislelizumab from BeiGene. Camrelizumab and tislelizumab are humanized IgG4 anti-PD-1 monoclonal antibodies that block the binding of PD-1 to its ligands. The first PD-1 inhibitor to hit the market was pembrolizumab (Keytruda), which was approved by the FDA in 2014. Since, ten PD-1/PD-L1 cancer immunotherapy drugs have come on the market worldwide, four of which were developed by Chinese pharmaceutical companies; these drugs are camrelizumab, tislelizumab, and sintilimab developed by Innovent Biologics and Eli Lilly and toripalimab developed by Shanghai Junshi Bioscience Co., Ltd. Following the FDA approval of Brukinsa (zanubrutinib), tislelizumab was the first drug developed by BeiGene to be approved in China. These young Chinese pharmaceutical companies show great potential in drug discovery, especially for novel targets. As China is the world's second-largest pharmaceutical market, we expect to see an increase in the number of novel drugs developed in China.

New classes of drugs developed using new technologies provide new treatment options and hope to patients with fatal diseases. For example, the cancer mortality rate in the US declined by 29% from 1991 to 2017. This success is partially due to targeted therapies such as the BRAF inhibitor Zelboraf (vemurafenib) and the anti-CTLA4 antibody Yervoy (ipilimumab).^[@CR4]^ In addition, emerging innovative therapeutic approaches such as CAR-T cell therapy for cancer and CRISPR-Cas9 gene editing could potentially make a difference for patients.

In 2020, Signal Transduction and Targeted Therapy aims to be the leading forum for research addressing unmet medical needs, including cancer, immune disorders, infectious diseases, virus such as SARS-CoV-2, diabetes, cardiovascular diseases, inflammation, central nervous system diseases, and other pathologies. We expect to publish papers on the discovery and development of new targets and therapeutic options that may have a significant impact on healthcare in the future.
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